Latest News and Updates

* (R) = Regulatory press releases

Oct 28, 2024

(R) Cantargia reports new results from clinical studies investigating nadunolimab in several forms of cancer; supporting ongoing strategies

Oct 11, 2024

(R) Cantargia reports new positive results on biomarkers and safety in CAN10 phase 1 clinical study

Oct 10, 2024

Cantargia’s strong Phase 2 clinical data in pancreatic cancer with nadunolimab published in Clinical Cancer Research

Sep 30, 2024

(R) Cantargia reports start of multiple dosing part in CAN10 phase 1 clinical trial

Sep 25, 2024

(R) Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology

Sep 14, 2024

(R) Cantargia presents positive results at ESMO Congress 2024 showing benefit of nadunolimab combination therapy in cancer after relapse on PD1-inhibitors

Sep 9, 2024

(R) Cantargia: new data from two clinical studies strongly support nadunolimab efficacy after relapse on PD1-inhibitors

Aug 28, 2024

(R) Correction: Cantargia publishes half-year report 2024

Aug 28, 2024

(R) Cantargia publishes half-year report 2024

Aug 27, 2024

Cantargia reports presentation of new preclinical data supporting CAN10 in fibrotic lung diseases

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Press releases

(R) Cantargia reports new results from clinical studies investigating nadunolimab in several forms of cancer; supporting ongoing strategies

(R) Cantargia reports new positive results on biomarkers and safety in CAN10 phase 1 clinical study

Cantargia’s strong Phase 2 clinical data in pancreatic cancer with nadunolimab published in Clinical Cancer Research

(R) Cantargia reports start of multiple dosing part in CAN10 phase 1 clinical trial

(R) Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology

(R) Cantargia presents positive results at ESMO Congress 2024 showing benefit of nadunolimab combination therapy in cancer after relapse on PD1-inhibitors

(R) Cantargia: new data from two clinical studies strongly support nadunolimab efficacy after relapse on PD1-inhibitors

(R) Correction: Cantargia publishes half-year report 2024

(R) Cantargia publishes half-year report 2024

Cantargia reports presentation of new preclinical data supporting CAN10 in fibrotic lung diseases

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Interview with CEO Hilde H. Steineger - 2025-10-07

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye interviews Interim CEO Damian Marron - 2025-02-07